Diamyd Medical
Diamyd Medical
Diamyd Medical (pronunciation: /ˈdaɪəmɪd/ medical) is a Swedish biopharmaceutical company that specializes in the development of pharmaceutical treatments for autoimmune diabetes and pain.
Etymology
The name "Diamyd" is derived from the Greek word "dia" meaning "through" and "myd" which is an abbreviation for "myelination", a process that is crucial for the proper functioning of the nervous system.
History
Diamyd Medical was founded in 1996 with the aim of developing a cure for Type 1 diabetes. The company's primary product, the Diamyd® vaccine, is based on the naturally occurring protein GAD65, which is used to slow down the autoimmune attack on insulin-producing cells.
Products
Diamyd Medical's main product is the Diamyd® vaccine for the treatment of autoimmune diabetes. The company also develops and markets the NTDDS (Nerve Targeting Drug Delivery System) for the treatment of severe chronic pain.
Related Terms
- Autoimmune diabetes: A form of diabetes in which the body's immune system attacks and destroys the insulin-producing cells in the pancreas.
- GAD65: A naturally occurring protein that is used in the Diamyd® vaccine to slow down the autoimmune attack on insulin-producing cells.
- NTDDS: An acronym for Nerve Targeting Drug Delivery System, a technology developed by Diamyd Medical for the treatment of severe chronic pain.
See Also
External links
- Medical encyclopedia article on Diamyd Medical
- Wikipedia's article - Diamyd Medical
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski